Key big pharma catalysts to kick off 2022
Important breast cancer data will come in the opening months of 2022, and Glaxo and Pfizer are due pivotal RSV results.
Biopharma’s buyout year ends with a bang
A recent buying spree swells 2021's meagre M&A tally, but the Pfizer-Arena deal could crystallise antitrust concerns.
Novo’s $3.3bn GalXC quest
The usually conservative group spends big on Dicerna – but others might be interested too.
Biopharma’s stock market winners and losers so far this year
Moderna is the standout gainer, but the stragglers are becoming more apparent as the pandemic tide retreats.
Global pharma stocks struggle in the third quarter
A strong performance from a handful of large drug developers could not rescue the sector from a weak three months on the stock market.
